PMID- 30555222
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1177-5475 (Print)
IS  - 1177-5491 (Electronic)
IS  - 1177-5475 (Linking)
VI  - 12
DP  - 2018
TI  - Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone 
      in advanced NSCLC patients with EGFR mutation.
PG  - 183-190
LID - 10.2147/BTT.S169305 [doi]
AB  - PURPOSE: Both epidermal growth factor receptor tyrosine kinase inhibitors 
      (EGFR-TKIs) and chemotherapy are widely applied for the treatment of advanced 
      non-small-cell lung cancer (NSCLC) with EGFR mutations, and the combination of 
      EGFR-TKIs and chemotherapy has been used for advanced NSCLC patients; however, 
      little is known about the efficacy of the direct comparison among them. PATIENTS 
      AND METHODS: The demographic and clinical characteristics of 92 patients 
      harboring advanced NSCLC with EGFR mutation were retrospectively reviewed. We 
      evaluated the effects of EGFR-TKIs, chemotherapy, and EGFR-TKIs plus chemotherapy 
      on advanced NSCLC patients with EGFR mutations, and the efficacy of combination 
      of chemotherapy and EGFR-TKIs vs chemotherapy or EGFR-TKIs alone in advanced 
      NSCLC patients was evaluated. RESULTS: The statistical results showed that the 
      intercalated combination of EGFR-TKIs plus chemotherapy significantly improved 
      progression-free survival (PFS; HR, 1.76; 95% CI 1.03-3.01; P=0.036; median, 20.5 
      vs 16 months) compared with EGFR-TKI monotherapy, but no difference in overall 
      survival (OS) was observed between these two groups (HR, 1.52; 95% CI 0.81-2.83; 
      P=0.19; median, 36 vs 29 months). However, patients who received the combination 
      of chemotherapy and EGFR-TKIs had longer PFS (HR, 2.78; 95% CI 1.57-4.93; 
      P<0.0001; median, 20.5 vs 12 months) as well as OS (HR, 2.86; 95% CI 1.56-5.27; 
      P=0.001; median, 36 vs 18 months) than those who received chemotherapy alone. 
      Toxicities were mild among the three treatment groups. Rash and diarrhea were 
      common adverse events (AEs) in the EGFR-TKI group, anemia and nausea in the 
      chemotherapy group, and anemia and diarrhea in the combination group. CONCLUSION: 
      This study demonstrated that the combination of chemotherapy with EGFR-TKIs as 
      first-line treatment has a significant effect on PFS in patients with advanced 
      NSCLC whose tumors harbor activating EGFR mutations. The combination treatment 
      had more toxicity, but was clinically manageable.
FAU - Wen, Miaomiao
AU  - Wen M
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
FAU - Xia, Jinghua
AU  - Xia J
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
FAU - Sun, Ying
AU  - Sun Y
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
FAU - Wang, Xuejiao
AU  - Wang X
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
FAU - Fu, Xianghui
AU  - Fu X
AD  - Department of Clinical Immunology, Xijing Hospital, The Fourth Military Medical 
      University, Xi'an 710032, Shaanxi, China.
FAU - Zhang, Yanning
AU  - Zhang Y
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
FAU - Zhang, Zhipei
AU  - Zhang Z
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
FAU - Zhou, Yongan
AU  - Zhou Y
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
FAU - Li, Xiaofei
AU  - Li X
AD  - Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an 710038, Shaanxi, China, zzpzyy@fmmu.edu.cn; l_tdxw@163.com.
LA  - eng
PT  - Journal Article
DEP - 20181130
PL  - New Zealand
TA  - Biologics
JT  - Biologics : targets & therapy
JID - 101321511
PMC - PMC6280904
OTO - NOTNLM
OT  - adjuvant therapy
OT  - chemotherapy
OT  - epidermal growth factor receptor-tyrosine kinase inhibitor
OT  - non-small-cell lung cancer
OT  - retrospective study
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/12/18 06:00
MHDA- 2018/12/18 06:01
PMCR- 2018/11/30
CRDT- 2018/12/18 06:00
PHST- 2018/12/18 06:00 [entrez]
PHST- 2018/12/18 06:00 [pubmed]
PHST- 2018/12/18 06:01 [medline]
PHST- 2018/11/30 00:00 [pmc-release]
AID - btt-12-183 [pii]
AID - 10.2147/BTT.S169305 [doi]
PST - epublish
SO  - Biologics. 2018 Nov 30;12:183-190. doi: 10.2147/BTT.S169305. eCollection 2018.